Recombinant interferon α-2b in the treatment of genital herpes: clinical and laboratory rationale and efficacy evaluation

According to the World Health Organization, a significant part of the population is susceptible to diseases caused by herpes viruses, among which genital herpes occupies a leading position in the incidence and severity of clinical manifestations. A promising strategy for the treatment of herpesvirus infections caused by herpes simplex virus (HSV) types 1 and 2 is the use of recombinant interferon-α preparations. Objective. To conduct a comparative analysis of the efficacy of using recombinant interferon α-2b with an active substance content of 1.000.000 IU and 3.000.000 IU in the treatment of genital herpesvirus infection. Patients and methods. A retrospective study of 100 patients with recurrent genital herpes 5.5 ± 1.25 per year at the age from 20 to 52 was carried out. The diagnosis was made based on complaints, clinical examination results and laboratory parameters. The presence of herpes virus antigen in the sample material, clinical status, clinical and biochemical parameters of peripheral blood, and the activity of antioxidant enzymes were assessed. Results. The maximum efficacy of therapy for genital herpesvirus infection was registered in patients who received complex treatment with valacyclovir and recombinant interferon α-2b with antioxidants at a dosage of 3.000.000 IU. Key words: antioxidant status, genital herpes, immunity, interferon α-2b